CDMO roundup: DPT rejig, UDG expansion and Dalton contract

By Dan Stanton

- Last updated on GMT

CDMO roundup: DPT rejig, UDG expansion and Dalton contract

Related tags Molecule Enzyme inhibitor

An operational rejig at DPT Laboratories, an expansion at UDG, and a synthesis and toxicology testing contract win for Dalton – welcome to Outsourcing-Pharma’s CDMO round-up.

The first contract development and manufacturing organisations (CDMOs) we’re focusing on this week is DPT, which has announced it has implemented a new strategy at a facility in San Antonio, Texas in order to enhance flexibility and efficiency.

Resources are being pumped into the plant to support high-speed bottle production, aerosols/foams filling and packaging, and traditional semi-solids and liquids manufacturing, to help focus the site on “maximizing quality, capacity and resource utilization,” ​General Manager Lyle Flom said.

“This is an evolution of our Center of Excellence strategy in the semi-solid and liquid space and supports our strategic commitment to continuously improve our manufacturing execution and regulatory/compliance environment.”

DPT was last in these pages in September when it acquired a New Jersey facility from Swedish drugmaker Meda. Check out the story here​.

UDG’s Sharp expansion

Sharp Clinical Services, acquired by UDG Healthcare from Indian contractor Bilcare in 2012​, has added an additional 5,000 sq ft of storage and packaging space at a UK site.

The new facility at the CDMO’s Crickhowell, Wales site was commissioned in response to new product introductions approved by regulators, and comprises of 150 additional pallet spaces and two assembly lines.

The investment was described as “a landmark moment for Sharp Clinical Services in the UK”​ by General Manager Ian Morgan, who added full production will begin in July.

President Frank Lis added: “This expansion has increased our global footprint and will allow us to provide our customers with a full range of services, from formulation development and pre-clinical supplies through to product launch.”

Dalton wins Ramsey Lake contract

And finally, CDMO Dalton Pharma Services will carry out early-stage development and manufacturing for private pharma firm Ramsey Lake’s small molecule cancer candidate, VR23.

The contract will see Dalton synthesise the β2-targeting proteasome inhibitor to support upcoming toxicology studies, and the deal was greeted as “a great opportunity for two Canadian companies to collaborate on developing innovative products,”​ by CEO Peter Pekos.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more